Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 30 for “"bevacizumab"”.
-
만성, 비전형적, 재발성 중심성장액맥락망막병증에서 유리체강내 bevacizumab 주입술의 효과
만성, 비전형적, 재발성 중심성장액맥락망막병증에서 유리체강내 bevacizumab 주입술의 효과에 대하여 알아보고자 하였다. 유리체강내 bevacizumab 1.25mg 주입술을 시행 받은 64안의 만성, 비전형적, 재발성 중심성장액맥락망막병증을 대상으로 후향적으로 연구를 진행하였으며, 최대교정시력(logMAR)과 중심황반두께를 초진 시, 유리체강내 bevacizumab 주입술 후 3개월, 6개월, 9개월, 12개월 후에 측정하였다. 경과 관찰기간 동안 환자들은 평균 3.23±1.7 회의 유리체강내 bevacizumab 주입술을 …
-
Temozolomide and Bevacizumab Therapy In Advanced Hemangiopericytoma/ Solitary Fibrous Tumor
… advanced HPC/SFT who received temozolomide and bevacizumab systemic therapy, the overall RECIST response rate was 14%, with the overall Choi response rate of 79%. The median PFS for the cohort was 9.7 months with a median 6-month progression free rate of 78.6%. The most frequently observed toxic …
-
Bevacizumab Effect on Topotecan Pharmacokinetics in a Murine Orthotopic Rhabdomyosarcoma Xenograft Model
… improving delivery of systemic chemotherapy. Bevacizumab (BEV), an anti-VEGF antibody, has been shown to transiently normalize tumor vasculature by increasing tumor vessel maturity, decreasing tumor vessel permeability, and increasing tumor oxygenation in an Rh30 orthotopic rhabdomyosarcoma …
-
Grosor macular luego de tratamiento con Ranibizumab o Bevacizumab en degeneración macular relacionada con la edad
… los cuales se encuentra el Ranibizumab y el Bevacizumab. El seguimiento se hace mediante medidas funcionales (agudeza visual) y anatómicas (grosor macular por tomografía óptica coherente). Objetivo: comparar el comportamiento del grosor macular luego del tratamiento con cada medicamento …
-
Blood pressure and intraocular pressure change in hypertensive and non-hypertensive patients after intravitreal bevacizumab injection
"유리체강내 베바시주맙 주입술이 혈압과 안압에 미치는 영향이 고혈압 이환 여부에 따라 차이가 있는지 알아보고자 한다. 당뇨황반부종, 맥락막 신생혈관 등 안과적 혈관질환을 진단받고 유리체강내 베바시주맙 주입술을 시행받은 환자 중 녹내장 약물을 투여 중이거나 유리체 절제술을 시행받은 과거력이 있는 환자, 혈압 조절 상태가 불량한 고혈압 환자들을 제외한 135 명을 연구대상으로 하였다. 술전에 혈압 및 안압을 측정한 후 수술실에서 무균적 처치하에 베바시주맙 1.25 mg을 하이측 평면부를 통해 유리체강내로 주입하였다. 시술 30분 후에 …
-
Effects of Combined Bevacizumab and Paclitaxel On Tumor Interstitial Fluid Pressure In A Preclinical Breast Cancer Model
Effects of Combined Bevacizumab and Paclitaxel on Tumor Interstitial Fluid Pressure in a Preclinical Breast Cancer Model by Ricardo H. Alvarez Several mechanisms of cell resistance are often accountable for unsuccessful chemotherapy against cancer. Another reason, which has received increased …
-
Controlling antibody delivery, mechanical properties, and cell response of alginate-chitosan polyelectrolyte complexes
… or antigens. The antiangiogenic antibody, bevacizumab, targets and binds to VEGF to prevent angiogenesis. Bevacizumab has been approved for the treatment of recurrent glioblastoma, with concurrent radiation and chemotherapy, however the clinical efficacy of bevacizumab is still debated. As …
-
Use of Echogenic Immunoliposomes For Delivery of Both Drug and Stem Cells For Inhibition of Atheroma Progression
… in high-affinity receptors of endothelial cells. Bevacizumab is a humanized monoclonal antibody specific for VEGF-A which was developed as an anti-tumor agent. Often, anti-VEGF agents result in regression of existing microvessels, inhibiting tumor growth and possibly causing tumor shrinkage with …
-
Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer: Characterizing a New Therapy and Investigating Potential Mechanisms of Resistance
… of physiological and pathological angiogenesis. Bevacizumab (Avastin®, Genentech/Roche), a humanized monoclonal antibody that recognizes human VEGF and blocks VEGF from binding to VEGF receptor (VEGFR) 1 and 2, was the first anti-angiogenic drug approved by the United States Food and Drug …
-
Chemioterapia intraperiotneale ipertermica per il trattamento del carcinoma ovarico in stadio avanzato: interazione farmacologica e profilo farmacocinetico
… di prima linea spesso con associazione del bevacizumab. In questo contesto, alcune esperienze hanno dimostrato che un approccio terapeutico globale alla chirurgia combinato con chemioterapia intraperitoneale ipertermica (HIPEC) potrebbe migliorare la prognosi. Inoltre, evidenze da modelli …
-
Targeted Inhibition of Sp1 Transcription Factor and Anti-Angiogenesis of Human Pancreatic Cancer
… pancreatic tumor growth was suppressed by Bevacizumab treatment. Both western blot and immunohistochemistry staining revealed that Sp1 and its downstream angiogenic genes expression were up-regulated by Bevacizumab treatment. Bevacizumab and mithramycin combination treatment synergistically …
-
Effect of Drugs on Rabbit Retina
… does not affect retinal morphology. Ranibizumab, bevacizumab, and pegaptanib are inhibitors of the cytokine vascular endothelial growth factor. Pegaptanib and ranibizumab are approved for injection into the vitreous. Bevacizumab is a cancer drug injected off-label intravitreally. In rabbit …
-
Yap1 Expression Predicts Sensitivity to Dual Akt/P70S6K Inhibition In Ovarian and Uterine Malignancies
… (R=0.675, p=0.0015). After establishment of a bevacizumab resistant endothelial cell line, RF-24, we demonstrate that resensitization to bevacizumab occurs with the addition of MSC2363318A.</p> <p><strong>Conclusions:</strong> MSC2363318A has therapeutic efficacy in multiple pre-clinical models …
-
Dual Targeting of Tumor Angiogenesis and Chemotherapy By Endostatin- Cytosine Deaminase-Uracil Phosphoribosyltransferase
… liver metastasisincident compared with bevacizumab/5-FU treatment in human breast and colorectalliver metastasis orthotropic animal models. In cardiotoxicity safety profile,EndoCD/5-FC is a contrast to bevacizumab/5-FU; lower risk of cardiotoxicityinduction or heart function failure was …
-
An Innovative Phase I Trial Design Allowing For The Identification of Multiple Potential Maximum to lerated Doses With Combination Therapy of Targeted Agents
… in our phase I trial are temsirolimus and bevacizumab. Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway which is fundamental for tumor growth and metastasis. One mechanism of tumor resistance to antiangiogenic therapy is upregulation of …
-
Role of The Ang-Tie2 Pathway In The Invasive Recurrence of Gbm Following Anti-Vegf Therapy
… clinical data supporting the effectiveness of bevacizumab, a humanized monoclonal anti-VEGF antibody, for the treatment of gliomas led to its accelerated approval for the treatment of patients with recurrent glioma. However, despite strong anti-tumor effects, upon treatment with bevacizumab, …
-
Differential Angiogenic Capability and Hypoxia Responses in Glioma Stem Cells
… abolished by the anti-VEGF neutralizing antibody bevacizumab, which is in clinical use for cancer therapy. Furthermore, bevacizumab displayed potent antiangiogenic efficacy in vivo and suppressed growth of xenografts derived from GSCs but limited efficacy against xenografts derived from a matched …
-
LOCOREGIONAL DELIVERY OF UNMETHYLATED CPG-OLIGODEOXYNUCLEOTIDES TO CANCER THERAPY: PRECLINICAL STUDIES
… in combination with different agents, including bevacizumab, Poly(I):Poly(C) and cisplatin. Our data indicate that the combination of repeated i.p. CpG-ODN treatments plus bevacizumab and Poly(I):Poly(C) do not significantly increase median survival time, while the association of CpG-ODN and …
-
Glioblastoma recidivante: Experiencia en dos centros de alta complejidad neuroquirúrgica 2013-2021
… por la escala funcional de Karnofsky. El uso de bevacizumab estuvo asociado a un mejor pronóstico de sobrevida. Conclusión: En nuestra muestra se presentó la mayor sobrevida y el menor número de complicaciones, en los sujetos con resección total y con uso asociado de terapia adyuvante.
-
Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours
… the vascular endothelial growth factor inhibitor bevacizumab. The main objective of this thesis was to investigate targeting of the receptor tyrosine kinase MERTK as a potential pharmacological intervention in schwannomas and meningiomas. Immunofluorescence and flow cytometry demonstrated that …
Page 1 of 2